Aro Biotherapeutics, a University City-based gene-therapy maker founded by two former Johnson & Johnson scientists, has raised $88 million from J&J and other investors in the U.S. and Europe to help bring its line of RNA-based drugs to market.
Read the full article at: www.inquirer.com
Latest posts by BioBuzz Media (see all)
- Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021 - April 8, 2021
- Novavax Plan Outlines Expansion of Gaithersburg Corporate Campus - April 6, 2021
- CARB-X is Funding Baltimore’s Novel Microdevices to Develop a Rapid and Portable Diagnostic for STDs Including Antibiotic-Resistant Infections - April 6, 2021
- Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma - April 6, 2021
- Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover - April 5, 2021